Status:

RECRUITING

Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer

Lead Sponsor:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Conditions:

PDAC

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

CA19-9 is an acidic glycoside containing sialic acid, called ganglioside. Lewis blood group antigen is the precursor for the synthesis of CA19-9, which is formed by the combined action of sialic acid ...

Detailed Description

1. This study adopts a prospective, multicenter design, and classifies pancreatic cancer patients and predicts their prognosis through Lewis antigen detection and CA19-9 detection. 2. Observe the surv...

Eligibility Criteria

Inclusion

  • Voluntarily enrolled, regardless of gender, aged ≥ 18 and ≤ 75 years old, and the patient can understand and is willing to sign an informed consent form;
  • ECOG 0-2
  • Pathologically confirmed as pancreatic ductal adenocarcinoma; Or confirmed by pathology and clinical examination as pancreatic ductal adenocarcinoma.
  • Willing to accept routine CA19-9 testing, Lewis antigen sample collection and testing (2-3ml), and follow-up Non pancreatic cancer subjects enrolled in this study must meet all the following criteria
  • 1\. Voluntary enrollment, regardless of gender, age ≥ 18 years, ≤ 75 years old, and the patient can understand and is willing to sign an informed consent form 2. Willing to accept Lewis antigen sample collection and testing (2-3ml)

Exclusion

  • Suffering from the second or double primary malignant tumor besides pancreatic cancer at the same time
  • Patients with pancreatic cancer who cannot trace the specific anti-cancer treatment plan
  • HIV positive
  • Other situations that researchers believe need to be excluded

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06515587

Start Date

August 1 2024

End Date

October 31 2026

Last Update

May 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shanghai General Hospital

Shanghai, Shanghai Municipality, China, 200040